Sugi Predict

Sugi Predict / Compounds / SCHEMBL484820

SCHEMBL484820

SCHEMBL484820

O=C(O)N1CCC2(CCNC2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.49
▸ L3MBTL3 Q96JM7 3/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ TSHR P16473 1/20 0.46
▸ NAMPT P43490 1/20 0.44
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP3A4 P08684 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ GABRA4 P48169 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27036544 1.00 HSD17B10 (0.49) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL27227211 1.00 HSD17B10 (0.49) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL1222909 0.89 HSD17B10 (0.60) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL4077133 0.89 CYP3A4 (0.49) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL1725493 0.89 L3MBTL3 (0.47) HSD17B10L3MBTL3L3MBTL1TSHRCYP1A2
SCHEMBL484826 0.89 CYP1A2 (0.49) NAMPTCYP1A2CYP2D6CYP3A4KDM1A
SCHEMBL18047936 0.87 HSD17B10 (0.43) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL16344528 0.86 L3MBTL3 (0.43) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL19971641 0.86 HSD17B10 (0.42) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT
SCHEMBL30367780 0.84 L3MBTL3 (0.47) HSD17B10L3MBTL3L3MBTL1TSHRNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 — — EP claimed
EP-3307067-B1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2022-11-02 — — EP claimed
WO-2026041636-A1 MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2026-02-26 — — WO disclosed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
WO-2025092695-A1 NEW HETEROCYCLIC COVALENT INHIBITOR OF MENIN, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 成都苑东生物制药股份有限公司 2025-05-08 — — WO disclosed
US-20250115551-A1 SYNTHESIS OF RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-10 — — US disclosed
US-12252497-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-03-18 — — US disclosed
US-20250074923-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-03-06 — — US disclosed
US-12202845-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-01-21 — — US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 — — EP disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 — — EP disclosed
WO-2010142402-A1 SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES Grünenthal GmbH (DE) 2010-12-16 — — WO disclosed
WO-2010141545-A1 BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2010-12-09 — — WO disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 — — WO disclosed
US-20100152158-A1 Substituted Disulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-06-17 — — US disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 — — WO disclosed
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152158-A1 Substituted Disulfonamide Compounds BDKRB1, BDKRB2, BRS3 HSD17B10 3111/4885L3MBTL3 3075/4885L3MBTL1 1632/4885
US-20250115551-A1 SYNTHESIS OF RAS INHIBITORS KRAS, NRAS, HRAS HSD17B10 3057/4885L3MBTL3 3627/4885L3MBTL1 3322/4885
US-20250074923-A1 RAS INHIBITORS KRAS, NRAS, HRAS HSD17B10 4376/4885L3MBTL3 3405/4885L3MBTL1 3269/4885
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 HSD17B10 2891/4885L3MBTL3 997/4885L3MBTL1 623/4885
US-12252497-B2 Ras inhibitors KRAS, NRAS, HRAS HSD17B10 4376/4885L3MBTL3 3405/4885L3MBTL1 3269/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 HSD17B10 2891/4885L3MBTL3 997/4885L3MBTL1 623/4885
US-12202845-B2 Ras inhibitors KRAS, NRAS, HRAS HSD17B10 4376/4885L3MBTL3 3405/4885L3MBTL1 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.